Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $37.00 Consensus PT from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $37.00.

Several brokerages have commented on CAPR. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Maxim Group upped their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. HC Wainwright increased their price objective on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Finally, Industrial Alliance Securities set a $48.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new position in Capricor Therapeutics during the third quarter valued at $28,000. Parkside Financial Bank & Trust purchased a new stake in Capricor Therapeutics in the 3rd quarter worth about $36,000. Russell Investments Group Ltd. lifted its stake in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC bought a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $92,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Down 4.3%

Shares of Capricor Therapeutics stock opened at $26.02 on Thursday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -14.46 and a beta of 0.61. The stock’s 50-day simple moving average is $9.59 and its 200-day simple moving average is $8.83. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). On average, equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.